Last reviewed · How we verify
Omeprazole, Lansoprazole, Esomeprazole, Rantidine
Omeprazole, Lansoprazole, Esomeprazole, and Rantidine are marketed drugs primarily indicated for the treatment of gastrointestinal disorders, with a strong presence in the pharmaceutical market. A key strength is their well-established mechanism and broad therapeutic use, supported by key composition patents expiring in 2028. The primary risk is the potential increase in generic competition following the patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Omeprazole, Lansoprazole, Esomeprazole, Rantidine |
|---|---|
| Sponsor | Temple University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: